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Given the obvious overlap between the concepts of 
polypharmacy and multimorbidity, it is striking that 
much of the research on these two issues is conducted in 
parallel, rather than in collaboration. In view of this, a 
meeting on medication optimization in  multimorbidity 
was convened at University College Cork in Ireland 
to bring together leading national and international 
researchers in the fields of medicines management and 
multimorbidity. Representatives from the disciplines of 
general practice (GP), pharmacy, clinical pharmacology, 
behavioural science, and health services research were 
present. Dr Martin Duerden, co-author of the King’s 
Fund report on ‘Polypharmacy and medicines optimisa-
tion’, was one of the speakers [7]. Using data from the 
report, Dr Duerden showed that there were three-fold 
increases in the numbers of patients receiving five or 
more medications between 1995 and 2010. The oldest 
patients were most affected, with 16.4% of those aged 65 
years and older receiving 10 or more medications. How-
ever, he acknowledged that older patients with multiple 
illnesses had much to gain from what he termed ‘appro-
priate polypharmacy’, or the use of multiple medicines 
to achieve maximum benefit with the least risk of harm. 
To limit potential harm, Dr Duerden suggested identi-
fying the patients at greatest risk of adverse outcomes 
from polypharmacy and tapering their drug regimens 
accordingly. He also emphasized the need to provide 
doctors in training with appropriate prescribing skills, 
which would include how to identify those at greatest 
risk and how to treat their multiple conditions more 
selectively.
Professor Stephen Byrne, School of Pharmacy, Uni-
versity College Cork, also focused his presentation on the 
use of medicines. He described the ongoing SENATOR 
Polypharmacy, broadly defined as the chronic co- 
prescription of several drugs [1], has long been 
recognized as problematic. The greater the number 
of medicines a patient takes, the greater the risk of 
adverse effects of any one medicine, and the greater the 
risk of drug–drug interactions. Thus, polypharmacy 
is an accepted risk for poor health outcomes, includ-
ing hospitalizations and mortality [2]. The number of 
drugs per patient (or polypharmacy) has come to be 
used as a measure of potentially hazardous professional 
behaviour, and is sometimes used in conjunction with 
the term ‘inappropriate prescribing’. Nonetheless, the 
prevalence of polypharmacy is rising inexorably [3]. 
This rise is driven, principally, by the rising preva-
lence of multimorbidity, i.e., the co-occurrence of 
two or more chronic long-term diseases or conditions 
in one patient [4]. The issue is compounded by clinical 
guidelines that advocate the use of several medicines 
in the management of individual diseases and their 
associated risk factors [5]. The result is a dilemma 
for prescribers: on the one hand there is the need to 
keep the number of medicines to a minimum, while 
on the other ensuring that the patient receives what 
evidence-based guidelines advocate as being in their 
best interest [6].
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(Software ENgine for the Assessment & optimization 
of drug and non-drug Therapy in Older peRsons) trial 
[8], in which he and colleagues from across Europe 
are developing and testing a decision-support engine 
to guide prescribers on how to minimize inappropri-
ate prescribing and polypharmacy in a cost-effective 
way. Dr Barbara Clyne and colleagues also examined 
web-based treatment algorithms to guide medication 
review in the OPTI-SCRIPT trial [9], but incorporated 
this with academic detailing by a pharmacist as well as 
patient information leaflets. This multifaceted approach 
was effective in reducing potentially inappropriate med-
ications in patients with polypharmacy in primary care.
Other researchers, using a multimorbidity perspective, 
focused on the qualitative nature of the patients’ mor-
bidities, their experience of treatment burden, and their 
priorities around symptom control and active disease 
management. Here, medications were viewed as part of 
a wider range of issues facing patients and clinicians. Pro-
fessor Susan Smith from the HRB Centre for Primary 
Care Research and the Royal College of Surgeons in 
Ireland, presented work from an exploratory randomized 
controlled trial, the Optimal study [10]. Findings from 
this study indicated that an occupational-therapy-led self-
management programme improved the quality of life for 
people in the community with multimorbidity. Profes-
sor Stewart Mercer, from the University of Glasgow in 
Scotland, discussed the striking social gradient of multi-
morbidity. His research group have shown that the age of 
onset of multimorbidity is 10–15 years earlier in people 
living in the most deprived compared with the most afflu-
ent areas [11]. In the CARE PLUS trial, Professor Mercer 
and colleagues examined a ‘whole-person’ intervention 
in the management of patients with multimorbidity liv-
ing in deprived areas in Scotland [12]. They found that 
additional consultation time, continuity with healthcare 
professionals, and the provision of supportive informa-
tion led to positive effects on patients’ quality of life and 
well-being.
Nevertheless, there are still real challenges for 
prescribers who are faced with the rising numbers 
of medicines indicated for their patients with multi-
morbidity. Studies undertaken at University College 
Cork have highlighted the conflicts that can arise 
between evidence-based practice and patient-centred 
care in multimorbidity [13]. These conflicts lead to 
‘satisficing’: delivering care that is deemed satisfac-
tory and sufficient given the particular complexities 
of a particular patient. For many prescribers, satisfic-
ing means maintaining the status quo of long lists of 
medications. For others, it involves relaxing targets 
for disease control, negotiating compromise with 
patients, or using hunches on the best course of action 
to take. These clinical dilemmas may be mitigated by 
emerging data on the relationship between the num-
ber of medications prescribed and multimorbidity. 
Dr Rupert Payne from the University of Cambridge, 
England, another co-author of the aforementioned 
King’s Fund report, illustrated this by discussing how 
prevalent conditions such as ischaemic heart disease 
and diabetes are unavoidably associated with multiple 
medications [14]. He elaborated on how the resulting 
polypharmacy can actually reduce the risk of hospi-
talization if it emanates from appropriate treatment of 
multiple chronic diseases [15].
Evidently, optimizing medication management and 
delivering patient-centred care in multimorbidity are 
not mutually exclusive. Dr Molly Byrne, of the Health 
Behaviour Change Research Group at NUI Galway in 
Ireland, suggested that the key to combining these two 
activities may lie in the use of behavioural theory. Mod-
els of behaviour, such as those described by Michie et 
al., may help to understand the difficulties that arise for 
healthcare professionals trying to meet these dual chal-
lenges [16].
An example of an intervention trying to achieve both 
goals is the 3D study, which was presented by Dr Mei 
See Man from the University of Bristol, in England. 
The 3D study addresses three aspects of multimor-
bidity care: (i) dimensions of health (encompassing 
patient-centred care and quality of life issues), (ii) 
depression, and (iii) drugs [17]. The latter component 
utilizes a community pharmacist review to simplify 
drug regimes, assess patient safety, and address adher-
ence, which is seamlessly integrated into the overall 
case-management plan.
This inaugural meeting has provided a useful plat-
form for sharing understandings between the diverse 
disciplines most involved in optimizing medications in 
multimorbidity. It is clear that patients with multimor-
bidity stand to benefit from appropriate prescription of 
multiple medications, but these patients also experience 
combinations of diseases, interactions, and symp-
toms that preclude strict adherence to single-disease 
guidelines. The line between what is appropriate and 
inappropriate prescribing in multimorbidity may only 
be drawn at the level of the individual patient. The 
delivery of safe, effective, and efficient healthcare for 
people with multiple chronic diseases presents a global 
challenge for clinicians, researchers, and policy mak-
ers. It is an issue that goes beyond simple medication 
management alone, and will not be resolved by one dis-
cipline or a single research perspective. Multimorbidity 
and polypharmacy may well be two sides of the same 
coin: bringing the two research perspectives together 
will generate synergies and new understandings that 
will maximize the benefit for patients with multiple 
chronic diseases.
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